McKesson and Cardinal Health separately announced Oct. 1 that they plan to extend their pharmaceutical-distribution relationships with CVS Health through June 2032, preserving major supply arrangements across CVS’s pharmacy operations. The announcements signal continuity in distribution services, although detailed commercial terms remain undisclosed. Distribution Strategy Group reported the news.
McKesson reached an agreement in principle covering pharmaceutical distribution to CVS’s retail, mail-order and specialty pharmacies, and distribution centers. Its current agreement expires in June 2027, making the planned extension an additional five years. The companies have worked together for more than 25 years.
Cardinal Health entered into a binding letter of intent extending its existing agreement through June 30, 2032. The company explicitly said the extension would maintain its current scope of distribution services. The announcements therefore represent different contractual stages: McKesson disclosed an agreement in principle, while Cardinal disclosed a binding letter of intent.
The relationship is particularly significant for McKesson. CVS was its largest customer in fiscal 2026, accounting for approximately 24% of consolidated revenue and 21% of total trade accounts receivable on March 31.
Cardinal reaffirmed its fiscal 2027 adjusted earnings-per-share guidance of $12.40 to $12.60 and its long-term adjusted EPS growth outlook of 12% to 14% alongside the announcement. Those figures reaffirm existing expectations; they do not disclose the extension’s profitability or pricing.
